Tag Archives: Says

United Therapeutics teamed with pumpmaker to block Remodulin generics, Sandoz suit says

It took Novartis’ Sandoz years to reach the market with a generic to United Therapeutics’ pulmonary arterial hypertension med Remodulin, but last month, the company managed to do just that. Now, there’s a big problem hindering the generic launch, Sandoz alleges in a new lawsuit (PDF): United Therapeutics is blocking generic uptake by teaming with… Read More »